BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc Commercial Day Transcript

Oct 18, 2022 / 03:00PM GMT
Release Date Price: €10.56 (+1.54%)
Matthew Wiley
BioXcel Therapeutics, Inc. - Senior VP & Chief Commercial Officer

Okay. Good morning to everyone here in person and those listening via webcast. Welcome to the BioXcel Therapeutics Commercial Day. My name is Matt Wiley, I'm the Chief Commercial Officer here at BioXcel. And on behalf of everyone in our organization, thanks for joining.

Today, we're very excited to share our progress on the IGALMI launch and to share with you some early key performance indicators. We've also assembled a great panel for you today to share information on the evolving market dynamics, as well as the proposition for IGALMI. We hope that you find the presentation dated to be both relevant and elucidating.

As a reminder, during today's presentation, certain matters discussed may be forward-looking statements that are subject to risks and uncertainties related to future events and/or the future financial or business performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements.

Today's presentation will focus on IGALMI,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot